PRIORIX is a lyophilised mixed preparation containing the attenuated live Measles, Mumps and Rubella virus strain propagated in either chick embryo tissue cultures (mumps and measles) or human diploid cells (rubella). PRIORIX is indicated for active immunization in children of 12 months to 10 years of age against Measles, Mumps and Rubella infections simultaneously.
A reconstituted dose of 0.5mL is recommended for children and adults.
Children: Two doses are usually given. The first dose is usually given at 12 months of age, followed by a booster dose at 4-6 years of age
Adults: A single dose may be given to adults who do not have immunity.
For latest IAP updates see revised immunization schedule.
Measles, Mumps and Rubella
Pregnancy, hypersensitivity to any components of the vaccine, allergy to neomycin, acute severe febrile illness and impaired immune response. The presence of a minor infection, however, is not a contraindication.